560 related articles for article (PubMed ID: 6290536)
1. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.
Nemerow GR; Jensen FC; Cooper NR
J Clin Invest; 1982 Nov; 70(5):1081-91. PubMed ID: 6290536
[TBL] [Abstract][Full Text] [Related]
2. [Investigation of Epstein-Barr virus and herpes simplex virus markers by serological and molecular methods in patients with rheumatoid arthritis and systemic lupus erythematosus].
Us T; Cetin E; Kaşifoğlu N; Kaşifoğlu T; Akgün Y
Mikrobiyol Bul; 2011 Oct; 45(4):677-83. PubMed ID: 22090298
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
Beebe DP; Schreiber RD; Cooper NR
J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
[TBL] [Abstract][Full Text] [Related]
4. Antiviral antibodies in the sera of homosexual men: correlation with their lifestyle and drug usage.
Nerurkar LS; Biggar RJ; Goedert JJ; Wallen W; Becker P; West F; Tzan N; Traub R; Lee YJ; Botelar W
J Med Virol; 1987 Feb; 21(2):123-35. PubMed ID: 3029318
[TBL] [Abstract][Full Text] [Related]
5. Complement-dependent, Epstein-Barr virus-neutralizing antibody appearing early in the sera of patients with infectious mononucleosis.
Sairenji T; Sullivan JL; Humphreys RE
J Infect Dis; 1984 May; 149(5):763-8. PubMed ID: 6327851
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.
Hook LM; Lubinski JM; Jiang M; Pangburn MK; Friedman HM
J Virol; 2006 Apr; 80(8):4038-46. PubMed ID: 16571820
[TBL] [Abstract][Full Text] [Related]
7. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.
Friedman HM; Wang L; Pangburn MK; Lambris JD; Lubinski J
J Immunol; 2000 Oct; 165(8):4528-36. PubMed ID: 11035093
[TBL] [Abstract][Full Text] [Related]
8. Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus.
Balachandran N; Oba DE; Hutt-Fletcher LM
J Virol; 1987 Apr; 61(4):1125-35. PubMed ID: 3029407
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.
Beebe DP; Cooper NR
J Immunol; 1981 Apr; 126(4):1562-8. PubMed ID: 6259260
[TBL] [Abstract][Full Text] [Related]
10. Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein B.
Emini EA; Luka J; Armstrong ME; Keller PM; Ellis RW; Pearson GR
Virology; 1987 Apr; 157(2):552-5. PubMed ID: 3029988
[TBL] [Abstract][Full Text] [Related]
11. Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera.
Leddy JP; Simons RL; Douglas RG
J Immunol; 1977 Jan; 118(1):28-34. PubMed ID: 187701
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients.
Delisi LE; Smith SB; Hamovit JR; Maxwell ME; Goldin LR; Dingman CW; Gershon ES
Psychol Med; 1986 Nov; 16(4):757-63. PubMed ID: 3029788
[TBL] [Abstract][Full Text] [Related]
13. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
14. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
Kurakata S; Ramos OF; Klein G; Klein E
Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147
[TBL] [Abstract][Full Text] [Related]
15. Induction of neutralizing antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV gp3 and herpes simplex viruses gB.
Kitamura K; Namazue J; Campo-Vera H; Ogino T; Yamanishi K
Virology; 1986 Feb; 149(1):74-82. PubMed ID: 2418583
[TBL] [Abstract][Full Text] [Related]
16. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.
Friedman HM; Wang L; Fishman NO; Lambris JD; Eisenberg RJ; Cohen GH; Lubinski J
J Virol; 1996 Jul; 70(7):4253-60. PubMed ID: 8676446
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibody to herpes simplex virus by a novel neutralization method with peroxidase-labelled complement Clq.
Taguchi F; Kawasaki T; Matsuzaki T; Lee SM
J Virol Methods; 1991 May; 32(2-3):157-62. PubMed ID: 1651947
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of sensitized virus by purified components of complement.
Daniels CA; Borsos T; Rapp HJ; Snyderman R; Notkins AL
Proc Natl Acad Sci U S A; 1970 Mar; 65(3):528-35. PubMed ID: 4315612
[TBL] [Abstract][Full Text] [Related]
19. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association?
Vergnon JM; Vincent M; de Thé G; Mornex JF; Weynants P; Brune J
Lancet; 1984 Oct; 2(8406):768-71. PubMed ID: 6148520
[TBL] [Abstract][Full Text] [Related]
20. Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.
Vasantha S; Coelingh KL; Murphy BR; Dourmashkin RR; Hammer CH; Frank MM; Fries LF
Virology; 1988 Dec; 167(2):433-41. PubMed ID: 2849234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
